JP7646632B2 - 甲状腺ホルモン受容体ベータアゴニスト化合物 - Google Patents
甲状腺ホルモン受容体ベータアゴニスト化合物 Download PDFInfo
- Publication number
- JP7646632B2 JP7646632B2 JP2022512349A JP2022512349A JP7646632B2 JP 7646632 B2 JP7646632 B2 JP 7646632B2 JP 2022512349 A JP2022512349 A JP 2022512349A JP 2022512349 A JP2022512349 A JP 2022512349A JP 7646632 B2 JP7646632 B2 JP 7646632B2
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- μmol
- compound
- pharma
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025034294A JP2025106242A (ja) | 2019-08-23 | 2025-03-05 | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891078P | 2019-08-23 | 2019-08-23 | |
| US62/891,078 | 2019-08-23 | ||
| US202062967943P | 2020-01-30 | 2020-01-30 | |
| US62/967,943 | 2020-01-30 | ||
| PCT/US2020/047467 WO2021041237A1 (en) | 2019-08-23 | 2020-08-21 | Thyroid hormone receptor beta agonist compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034294A Division JP2025106242A (ja) | 2019-08-23 | 2025-03-05 | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544714A JP2022544714A (ja) | 2022-10-20 |
| JP2022544714A5 JP2022544714A5 (https=) | 2023-08-28 |
| JP7646632B2 true JP7646632B2 (ja) | 2025-03-17 |
Family
ID=74684314
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022512349A Active JP7646632B2 (ja) | 2019-08-23 | 2020-08-21 | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
| JP2025034294A Pending JP2025106242A (ja) | 2019-08-23 | 2025-03-05 | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034294A Pending JP2025106242A (ja) | 2019-08-23 | 2025-03-05 | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12528791B2 (https=) |
| EP (1) | EP4017875A4 (https=) |
| JP (2) | JP7646632B2 (https=) |
| CN (1) | CN114430743A (https=) |
| AU (1) | AU2020336272A1 (https=) |
| CA (1) | CA3154488A1 (https=) |
| WO (1) | WO2021041237A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024510935A (ja) * | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| KR20220017917A (ko) | 2019-05-08 | 2022-02-14 | 알리고스 테라퓨틱스 인코포레이티드 | Thr-베타의 조절제 및 이의 사용 방법 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3185296A1 (en) | 2020-07-10 | 2022-01-13 | David Craig Mcgowan | Modulators of thr-? and methods of use thereof |
| EP4201927A4 (en) * | 2020-08-19 | 2024-08-21 | Chengdu Fanxi Biopharma Co., Ltd. | CYANOTRIAZINE DERIVATIVE, MANUFACTURING PROCESS AND USE THEREOF |
| CN116940566A (zh) * | 2021-03-19 | 2023-10-24 | 南京明德新药研发有限公司 | 双环吡啶酮类化合物及其应用 |
| WO2022194278A1 (zh) * | 2021-03-19 | 2022-09-22 | 南京明德新药研发有限公司 | 双环苯酚类化合物及其应用 |
| CN117279911B (zh) * | 2021-05-21 | 2025-07-08 | 深圳微芯生物科技股份有限公司 | 一种杂环化合物及其应用 |
| CN113979963B (zh) * | 2021-12-24 | 2022-03-11 | 凯思凯旭(上海)医药科技有限公司 | 一种作为甲状腺激素β受体激动剂的化合物及其用途 |
| TWI910297B (zh) * | 2021-12-24 | 2026-01-01 | 大陸商廣東東陽光藥業股份有限公司 | 一種作為甲狀腺激素β受體激動劑的化合物及其用途 |
| CN116354934A (zh) * | 2021-12-28 | 2023-06-30 | 中国科学院上海药物研究所 | 一类喹啉类化合物及其制备方法、药物组合物和用途 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN120923503A (zh) * | 2025-10-10 | 2025-11-11 | 吉斯凯(苏州)制药有限公司 | 具有杂环结构的化合物、THRβ受体激动剂及用途 |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001114768A (ja) | 1999-09-30 | 2001-04-24 | Pfizer Prod Inc | 甲状腺受容体リガンドとしての６−アザウラシル誘導体 |
| JP2004501132A (ja) | 2000-06-21 | 2004-01-15 | カロ バイオ アクチェブラーグ | 甲状腺受容体リガンド、それらを含む薬学的組成物、および甲状腺ホルモンにより影響を及ぼされる障害の治療におけるそれらの使用 |
| WO2007128492A1 (en) | 2006-05-03 | 2007-11-15 | Karo Bio Ab | Novel pharmaceutical compositions |
| WO2007134864A1 (en) | 2006-05-24 | 2007-11-29 | Karo Bio Ab | Indole derivatives and their use as thyroid receptor ligands |
| JP2009500305A (ja) | 2005-07-04 | 2009-01-08 | カロ バイオ アクチェブラーグ | 甲状腺受容体用アゴニストとしての複素環式化合物 |
| JP2009501759A (ja) | 2005-07-21 | 2009-01-22 | エフ．ホフマン−ラ ロシュ アーゲー | 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体 |
| WO2010122980A1 (ja) | 2009-04-20 | 2010-10-28 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
| JP2010539209A (ja) | 2007-09-20 | 2010-12-16 | エフ．ホフマン−ラ ロシュ アーゲー | 甲状腺ホルモンアナログのプロドラッグ |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| WO2019144835A1 (zh) | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| JP2022504706A (ja) | 2018-10-12 | 2022-01-13 | インベンティスバイオ カンパニー リミテッド | 甲状腺ホルモン受容体作動薬 |
| JP2022521341A (ja) | 2019-02-21 | 2022-04-06 | ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド | 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用 |
| JP2022532706A (ja) | 2019-05-08 | 2022-07-19 | アリゴス セラピューティクス，インコーポレーテッド | ＴＨＲ－βの調節物質およびその使用方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4197307A (en) | 1977-04-12 | 1980-04-08 | Ciba-Geigy Corporation | 2-Alkylthio-, 2-alkylsulphinyl- and 2-alkylsulfonyl-6-phenylbenzimidazoles as anthelmintic agents |
| EP0377903A3 (de) | 1989-01-09 | 1991-07-17 | Bayer Ag | Substituierte Hexahydro-1,2,4-triazindione, Verfahren zu ihrer Herstellung, Zwischenprodukte dafür und ihre Verwendung |
| US6787652B1 (en) | 1999-09-30 | 2004-09-07 | Pfizer, Inc. | 6-Azauracil derivatives as thyroid receptor ligands |
| EP1347959A1 (de) | 2000-12-27 | 2003-10-01 | Bayer Aktiengesellschaft | Indol-derivate |
| EP1471049A4 (en) | 2002-01-30 | 2006-08-16 | Kissei Pharmaceutical | NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF |
| WO2003094845A2 (en) | 2002-05-08 | 2003-11-20 | Bristol-Myers Squibb Company | Pyridine-based thyroid receptor ligands |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
| WO2007132475A1 (en) | 2006-05-15 | 2007-11-22 | Cadila Healthcare Limited | Selective tr-beta 1 agonist |
| WO2008130637A1 (en) | 2007-04-18 | 2008-10-30 | New York University | Hydrazide compounds as thyroid hormone receptor modulators and uses thereof |
| WO2009001359A2 (en) | 2007-06-27 | 2008-12-31 | Quark Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of pro-apoptotic genes |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| FR2933979B1 (fr) | 2008-07-15 | 2012-08-24 | Pf Medicament | Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| SG11201402004YA (en) | 2011-11-14 | 2014-05-29 | Cephalon Inc | Uracil derivatives as axl and c-met kinase inhibitors |
| CN103130723B (zh) | 2011-11-30 | 2015-01-14 | 成都地奥制药集团有限公司 | 一种多聚(adp-核糖)聚合酶抑制剂 |
| CN102898377B (zh) | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
| AR092872A1 (es) | 2012-09-17 | 2015-05-06 | Madrigal Pharmaceuticals Inc | Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos |
| KR102374499B1 (ko) | 2014-04-11 | 2022-03-14 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | Nafld 및 nash 의 치료 |
| CN107074823B (zh) | 2014-09-05 | 2021-05-04 | 基因泰克公司 | 治疗性化合物及其用途 |
| CN105477636B (zh) | 2015-10-16 | 2019-09-17 | 厦门大学 | 使用阿维菌素及其衍生物治疗代谢疾病的方法 |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US11419878B2 (en) | 2016-03-28 | 2022-08-23 | Intercept Pharmaceuticals, Inc. | Medicine obtained by combining FXR agonist and ARB |
| SMT202500241T1 (it) | 2016-03-31 | 2025-07-22 | Genfit | Elafibranor per uso nel trattamento di colangite biliare primitiva |
| BR112018073460A2 (pt) | 2016-05-25 | 2019-07-09 | Akarna Therapeutics Ltd | terapias combinadas usando moduladores do receptor farnesoide x (fxr) |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| US20210212968A1 (en) | 2016-10-19 | 2021-07-15 | Boehringer Ingelheim International Gmbh | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof |
| WO2018103624A1 (zh) | 2016-12-06 | 2018-06-14 | 江苏恒瑞医药股份有限公司 | 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途 |
| JP7618384B2 (ja) | 2017-02-21 | 2025-01-21 | ジェンフィ | Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ |
| WO2018167103A1 (en) | 2017-03-13 | 2018-09-20 | Genfit | Pharmaceutical compositions for combination therapy |
| WO2018170173A1 (en) | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| JP7266531B2 (ja) | 2017-04-18 | 2023-04-28 | ジェンフィ | エラフィブラノール又はその誘導体と抗ｎａｓｈ剤、抗線維化剤又は抗胆汁うっ滞性剤の組合せ |
| WO2018208707A1 (en) | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US20210121493A1 (en) | 2017-07-25 | 2021-04-29 | Cedars-Sinai Medical Center | Methods for treating liver diseases |
| CN111032884A (zh) | 2017-08-25 | 2020-04-17 | 基恩菲特公司 | 非酒精性脂肪性肝病、非酒精性脂肪性肝炎和/或肝纤维化的非侵入性诊断 |
| WO2019053235A1 (en) | 2017-09-15 | 2019-03-21 | Genfit | NON-INVASIVE DIAGNOSIS OF NON ALCOHOLIC LIVER DISEASES, NON ALCOHOLIC STHEATHEPATITIS AND / OR HEPATIC FIBROSIS |
| EP3684954B1 (en) | 2017-09-18 | 2025-11-26 | Genfit | Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis |
| JP7264906B2 (ja) | 2017-11-01 | 2023-04-25 | ブリストル－マイヤーズ スクイブ カンパニー | ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物 |
| EP3710599B1 (en) | 2017-11-13 | 2024-07-17 | Gilead Sciences, Inc. | Method for staging liver fibrosis in nash patients |
| WO2019209738A1 (en) | 2018-04-24 | 2019-10-31 | Ph Pharma Co., Ltd. | Use of neutrophil elastase inhibitors in liver disease |
| ES3029158T3 (en) | 2018-06-12 | 2025-06-23 | Xizang Haisco Pharmaceutical Co Ltd | Thyroid hormone receptor agonists and uses thereof |
| CN112805005A (zh) | 2018-08-24 | 2021-05-14 | 拓臻股份有限公司 | 甲状腺素受体β促效剂化合物 |
| EP3844156A4 (en) | 2018-08-30 | 2022-06-08 | Terns Pharmaceuticals, Inc. | TREATMENT OF HEPATIC DISORDERS |
| NZ773110A (en) | 2018-09-18 | 2024-11-29 | Terns Inc | Compounds for treating certain leukemias |
| EA202190661A1 (ru) | 2018-09-18 | 2021-08-13 | Метакрайн, Инк. | Агонисты фарнезоидного х-рецептора для лечения заболевания |
| TWI884745B (zh) | 2018-10-12 | 2025-05-21 | 美商拓臻股份有限公司 | 甲狀腺素受體β促效劑化合物 |
| CN111320609A (zh) | 2018-12-13 | 2020-06-23 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| EP3897666A2 (en) | 2018-12-17 | 2021-10-27 | Mitopower LLC | Nicotinyl riboside compounds and their uses |
| CN111484481A (zh) | 2019-01-26 | 2020-08-04 | 察略盛医药科技(上海)有限公司 | 哒嗪酮类衍生物、其制备方法及其在医药上的用途 |
| WO2020228577A1 (zh) | 2019-05-10 | 2020-11-19 | 深圳微芯生物科技股份有限公司 | 一种哒嗪酮衍生物及其应用 |
| WO2020239076A1 (zh) | 2019-05-29 | 2020-12-03 | 南京明德新药研发有限公司 | 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用 |
| EP4003349A1 (en) | 2019-07-23 | 2022-06-01 | Novartis AG | Combination treatment of liver diseases using fxr agonists |
| CN112409340B (zh) | 2019-08-21 | 2022-03-18 | 海创药业股份有限公司 | 卤素取代的苯醚类化合物及其用途 |
| AU2020336272A1 (en) | 2019-08-23 | 2022-04-14 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| WO2021050945A1 (en) | 2019-09-12 | 2021-03-18 | Terns, Inc. | Thyroid hormone receptor beta agonist compounds |
| TW202128668A (zh) | 2019-12-16 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 并環類衍生物、其製備方法及其在醫藥上的應用 |
| US20210379043A1 (en) | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| US20210379040A1 (en) | 2020-05-13 | 2021-12-09 | Terns Pharmaceuticals, Inc. | Combination treatment of liver disorders |
| AU2021359895A1 (en) | 2020-10-15 | 2023-06-15 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| CN114437034A (zh) | 2020-11-06 | 2022-05-06 | 深圳微芯生物科技股份有限公司 | 一种酞嗪类化合物的可药用盐、晶型及其制备方法 |
| KR20230154806A (ko) | 2021-01-14 | 2023-11-09 | 엔요 파마 | Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과 |
| PE20240097A1 (es) | 2021-03-03 | 2024-01-18 | Terns Pharmaceuticals Inc | Compuestos agonistas beta del receptor de la hormona tiroidea |
| WO2022194278A1 (zh) | 2021-03-19 | 2022-09-22 | 南京明德新药研发有限公司 | 双环苯酚类化合物及其应用 |
| CN119013027A (zh) | 2021-11-11 | 2024-11-22 | 拓臻制药公司 | 用于治疗肝脏病症的SSAO抑制剂和THR-β激动剂的组合 |
| EP4429637A1 (en) | 2021-11-11 | 2024-09-18 | Terns Pharmaceuticals, Inc. | Treating liver disorders with an ssao inhibitor |
| PE20241327A1 (es) | 2021-11-11 | 2024-06-26 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-beta |
| WO2023220404A1 (en) | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
-
2020
- 2020-08-21 AU AU2020336272A patent/AU2020336272A1/en active Pending
- 2020-08-21 EP EP20856291.8A patent/EP4017875A4/en active Pending
- 2020-08-21 JP JP2022512349A patent/JP7646632B2/ja active Active
- 2020-08-21 CN CN202080066442.XA patent/CN114430743A/zh active Pending
- 2020-08-21 US US17/637,426 patent/US12528791B2/en active Active
- 2020-08-21 CA CA3154488A patent/CA3154488A1/en active Pending
- 2020-08-21 WO PCT/US2020/047467 patent/WO2021041237A1/en not_active Ceased
-
2025
- 2025-03-05 JP JP2025034294A patent/JP2025106242A/ja active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001114768A (ja) | 1999-09-30 | 2001-04-24 | Pfizer Prod Inc | 甲状腺受容体リガンドとしての６−アザウラシル誘導体 |
| JP2004501132A (ja) | 2000-06-21 | 2004-01-15 | カロ バイオ アクチェブラーグ | 甲状腺受容体リガンド、それらを含む薬学的組成物、および甲状腺ホルモンにより影響を及ぼされる障害の治療におけるそれらの使用 |
| JP2009500305A (ja) | 2005-07-04 | 2009-01-08 | カロ バイオ アクチェブラーグ | 甲状腺受容体用アゴニストとしての複素環式化合物 |
| JP2009501759A (ja) | 2005-07-21 | 2009-01-22 | エフ．ホフマン−ラ ロシュ アーゲー | 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体 |
| WO2007128492A1 (en) | 2006-05-03 | 2007-11-15 | Karo Bio Ab | Novel pharmaceutical compositions |
| WO2007134864A1 (en) | 2006-05-24 | 2007-11-29 | Karo Bio Ab | Indole derivatives and their use as thyroid receptor ligands |
| JP2010539209A (ja) | 2007-09-20 | 2010-12-16 | エフ．ホフマン−ラ ロシュ アーゲー | 甲状腺ホルモンアナログのプロドラッグ |
| WO2010122980A1 (ja) | 2009-04-20 | 2010-10-28 | 田辺三菱製薬株式会社 | 新規甲状腺ホルモンβ受容体作動薬 |
| WO2018075650A1 (en) | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
| WO2019144835A1 (zh) | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
| JP2022504706A (ja) | 2018-10-12 | 2022-01-13 | インベンティスバイオ カンパニー リミテッド | 甲状腺ホルモン受容体作動薬 |
| JP2022521341A (ja) | 2019-02-21 | 2022-04-06 | ナンジン・ルイジェ・ファーマ・カンパニー・リミテッド | 新規化合物及び甲状腺ホルモン受容体アゴニストとしてのそれらの使用 |
| JP2022532706A (ja) | 2019-05-08 | 2022-07-19 | アリゴス セラピューティクス，インコーポレーテッド | ＴＨＲ－βの調節物質およびその使用方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024510935A (ja) * | 2021-03-03 | 2024-03-12 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | 甲状腺ホルモン受容体ベータアゴニスト化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220281849A1 (en) | 2022-09-08 |
| EP4017875A4 (en) | 2023-05-03 |
| WO2021041237A1 (en) | 2021-03-04 |
| AU2020336272A1 (en) | 2022-04-14 |
| CA3154488A1 (en) | 2021-03-04 |
| CN114430743A (zh) | 2022-05-03 |
| JP2022544714A (ja) | 2022-10-20 |
| JP2025106242A (ja) | 2025-07-15 |
| US12528791B2 (en) | 2026-01-20 |
| EP4017875A1 (en) | 2022-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7646632B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| JP7846735B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| US12559493B2 (en) | PGDH inhibitors and methods of making and using | |
| JP7611832B2 (ja) | 特定の白血病を治療するための化合物 | |
| JP2022110080A (ja) | Ｅｈｍｔ２阻害剤としてのアミン置換複素環化合物およびその使用方法 | |
| TWI840423B (zh) | 甲狀腺素受體β促效劑化合物 | |
| JP2024510935A (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| RU2748993C1 (ru) | Производное с конденсированным кольцом в качестве ингибитора рецептора a2a | |
| JP2019533650A (ja) | Ｅｈｍｔ２阻害剤としての置換された融合二環式または三環式複素環化合物 | |
| US20230390274A1 (en) | Inhaled formulations of pgdh inhibitors and methods of use thereof | |
| US8772304B2 (en) | Benzimidazole inhibitors of leukotriene production | |
| BR122025027049A2 (pt) | Compostos, sal de adição de ácido farmaceuticamente aceitável, seu método de produção e métodos de síntese de compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230818 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230818 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240730 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240731 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241029 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250122 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250204 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250305 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7646632 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |